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TheObjective: Aberrant expression of mismatch repair genes, such as human mutL ho-
molog 1 (hMLH1) and human mutS homolog 2 (hMSH2), are common in some human
cancers, and promoter methylation is believed to inactivate expression of hMLH1. We
investigated whether promoter methylation is involved in loss of hMLH1 protein and
whether aberrant expression of hMLH1 and hMSH2 protein is related to prognosis after
resection for esophageal squamous cell cancer.
Methods: We analyzed promoter methylation of hMLH1 using methylation-specific
polymerase chain reaction and hMLH1 and hMSH2 protein by using immunohisto-
chemistry in 60 resected tumor specimens. The Pearson 2 test was used to compare
expression of hMLH1 and hMSH2 protein among patients with different clinicopath-
ologic parameters. Concordance analysis was performed between hMLH1 methylation
and its protein expression.
Results: Loss of hMLH1 and hMSH2 protein was found in 43 (72%) and 39 (65%, P 
.06) of 60 resected specimens, respectively. hMLH1 protein correlated well with tumor
staging (P  .0001), depth of tumor invasion (P  .008), and nodal involvement (P 
.0001) but not with distant metastasis, whereas hMSH2 did not show correlation with any of
these parameters. A concordance rate of 83.3% was present between expression of hMLH1
protein and its promoter methylation (P  .001).
Conclusions: Aberrant expression of hMLH1 and hMSH2 protein is frequently asso-
ciated with the presence of esophageal squamous cell carcinoma, and expression of
hMLH1 protein is a better prognostic predictor than is expression of hMSH2 protein.
Promoter methylation is one of the mechanisms responsible for loss of hMLH1 protein
in esophageal squamous cell cancer.
Promoter methylation is one of the most important mechanisms leading to inac-tivation of gene expression and has been known to cause aberrant expression ofsome important tumor suppressor genes, such as p16,1 E-cadherin,2 and the von
Hippel Lindau gene.3 Promoter methylation has been implicated in the carcinogenic
process in many cancers, including gastric cancer, colorectal cancer, breast cancer, lung
Dr Tzaocancer, ovarian cancer, bladder cancer, and oral cancers.4,5
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which cells correct errors in DNA replication during prolifer-
ation.6 Cells with MMR defects show mutation rates up to
1000-fold greater than those observed in normal cells.6 Two
MMR genes, human mutL homolog 1 (hMLH1) and human
mutS homolog 2 (hMSH2), have been cloned and demon-
strated to participate in DNA MMR.7,8 The mutant phenotype
has been detected in tumors from patients with hereditary
nonpolyposis colorectal cancer,9 as well as in lung,10 ovari-
an,11 head and neck,12 and gastrointestinal cancers, including
gastric cancer13 and adenocarcinoma of the esophagus.14 The
loss of corresponding protein is seen in almost all of the tumors
with germline MMR gene mutation.15
The loss of hMLH1 expression has been shown to correlate
with cytosine methylation of CpG islands regions in its pro-
moter region in colon cancer cell lines and tissues.16,17 Pro-
moter methylation associated with loss of the hMLH1 protein
has been found in some MMR-defective colorectal and endo-
metrial cancer cell lines in which mutations in the MMR genes,
including hMSH2, hMLH1, hPMS2, and hPMS1, were ab-
sent.17,18 Interestingly, these results demonstrate that the pro-
moter of hMSH2 is rarely methylated, indicating that aberrant
methylation of the hMLH1 promoter is potentially a very
important mechanism in the inactivation of the MMR system
in human cancers.17,18
Little is known about whether promoter methylation of
hMLH1 is associated with loss of hMLH1 protein and the role
of promoter methylation in tumorigenesis of squamous cell
carcinoma of the esophagus. There are no correlative studies of
aberrant expression of these MMR genes and the prognosis of
esophageal squamous cell cancer. We examined promoter
methylation of hMLH1 and expression of hMLH1 and hMSH2
protein in squamous cell carcinoma of the esophagus in rela-
tion to prognosis.
Methods
Study Population and Tumor Samples
After esophagectomy for 60 patients with squamous cell carci-
noma, archival paraffin-embedded tissue blocks of all primary
tumor specimens and 20 of 60 matched normal mucosa control
specimens were collected from January 1998 through December
2003. The study was reviewed and approved by the institution’s
surveillance committee, which allowed us to get access to
patients’ medical records and to obtain tissue samples and
pertinent follow-up data. From review of medical records, clin-
Abbreviations and Acronyms
hMLH1 human mutL homolog 1
hMSH2  human mutS homolog 2
MMR mismatch repair
PCR  polymerase chain reactionical information was collected, and TNM status was recorded
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system19 for esophageal cancer. Survival and follow-up data
were obtained from the Institutional Cancer Registry.
DNA Extraction and Methylation-specific Polymerase
Chain Reaction Assay for hMLH1
Serial 5-m sections were cut from formalin-fixed, paraffin-
embedded tissue blocks. All slides were stained with hematoxylin
and eosin, and one of the slides was used as a guide to localize
tumor regions. The tumor cells were microdissected from 3 slides
of serial sections. After deparaffinization in xylene, genomic DNA
of recovered tumor cells was prepared by using proteinase K
digestion and phenol-chloroform extraction, followed by ethanol
precipitation. The promoter methylation status of the hMLH1 gene
of all tumor samples and their normal mucosa control samples was
determined by means of chemical treatment with sodium bisulfite
and subsequent methylation-specific polymerase chain reaction
(PCR) analysis, as described by Herman and colleagues.20 For
bisulfite treatment of DNA used for methylation-specific PCR,
extracted DNA (1 g) in a volume of 50 L was denatured with
NaOH (final concentration, 0.2 mol/L) for 10 minutes at 37°C for
samples with nanogram quantities of human DNA, and 1 g of
salmon sperm DNA (Sigma-Aldrich Corporation, St Louis, Mo)
was added as a carrier before modification. Thirty microliters of 10
mmol/L hydroquinone (Sigma-Aldrich) and 520 L of 3 mol/L
sodium bisulfite (Sigma-Aldrich) at pH 5, both freshly prepared,
were added and mixed, and samples were incubated under mineral
oil at 50°C for 16 hours. Modified DNA was purified by using the
Wizard DNA purification resin according to the manufacturer
(Promega Corp, Madison, Wis) and eluted into 50 L of water.
Modification was completed by NaOH (final concentration, 0.3
mol/L) treatment for 5 minutes at room temperature, followed by
ethanol preditation. DNA was resuspended in water and stored at
20°C until used for PCR amplification. Primer sequences of
hMLH1 for the unmethylated reaction were 5=-TTTTGATGTAGAT-
GTTTTATTAGGGTTGT-3= (sense) and 5=-ACCACCTCATCATA-
ACTACCCACA-3= (antisense), and for the methylated reaction, they
were 5=-ACGTAGACGTTTTATTAGGGTCGC-3= (sense) and 5=-
CCTCATCGT AAC-TACCCGCG-3= (antisense).9 Paraffin-embed-
ded samples were amplified first with flanking PCR primers that
amplify bisulfite-modified DNA but that would not preferentially
amplify methylated or unmethylated DNA. The primers used were
5=-GAGTAGTTTTTTTTTTAGGAGTGAAG-3’27 (sense) and 5=-
AAAAACTATAAAACCCTATACCTAATCTA-3= (antisense).9
PCR was performed for 40 cycles at an annealing temperature of
65°C and 62°C for unmethylated and methylated reactions, respec-
tively, by using 50 ng of bisulfite-modified DNA. All PCRs were
performed with positive controls for both unmethylated and methyl-
ated alleles and no DNA control. A ratio of greater than 0.5 was
defined as aberrant methylation.
Analysis of Protein Expression: Immunohistochemistry
Assay
Paraffin blocks of tumors were cut into 5-m slices and then
processed by using standard deparaffinization and rehydration
techniques. After antigen retrieval with microwave heating, all
tissue sections on slides were immunostained according to instruc-
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was G168-728 (1:250; PharMingen, San Diego, Calif) for the
hMLH1 protein and FE11 (1:50; Oncogen Science, Cambridge,
Mass) for the hMSH2 protein, respectively. The binding of pri-
mary antibody was visualized with a detection system (DAKO
LSAB Kit K675; DakoCytomation California Inc, Carpinteria,
Calif). The normal staining pattern for hMLH1 and hMSH2 is
nuclear. Tumor cells that exhibited an absence of nuclear staining
in the presence of nonneoplastic cells or infiltrating lymphocytes
with nuclear staining were considered to have an abnormal pattern.
Staining results were examined by 2 observers blinded to the status
Figure 1. Immunostaining of hMLH1 and hMSH2 fo
carcinoma. A, Positive staining was detected in nu
cells (arrowhead) for hMLH1. B, Tumor cells stained
stained positively (arrowhead) for hMLH1. C, Positive
cells (arrows). D, Tumor cells stained negatively
positively (arrowhead) for hMSH2. Positive nuclear
control for immunostaining of hMLH1 and hMHS2, rof the molecular analyses.
The Journal of Thoracic anStatistical Analysis
The Pearson 2 test was used to compare expression of hMLH1
and hMHS2 protein and methylation status of hMLH1 among
patients undergoing esophagectomy for esophageal squamous
cell carcinoma with different clinicopathologic characteristics,
including age, stage, and overall TNM category. Comparison of
age between patients with and without alterations was made by
using the 2-sample t test. The Kaplan-Meier method was used to
estimate the probability of survival as a function of time and the
median survival.21 The log-rank test was used to assess the
significance of difference between pairs of survival
resected specimen of esophageal squamous cell
of tumor cells (arrows) and in vascular endothelial
atively (arrows), whereas an infiltrating lymphocyte
ning for hMSH2 was detected in the nuclei of tumor
ows), whereas an infiltrating lymphocyte stained
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Expression of hMLH1 and hMSH2 Protein in Relation
to Patients’ Clinicopathologic Parameters and Survival
Clinical information for 60 patients undergoing esophagec-
tomy for squamous cell carcinoma of the esophagus is
summarized in Table E1. The association of altered expres-
sion of hMLH1 and hMSH2 protein with patients’ clinico-
pathologic parameters is summarized in Table E2. Aberrant
expression of hMLH1 (Figure 1, B) and hMSH2 (Figure 1,
D) protein was observed in 43 (72%) and 39 (65%) patients,
respectively (P  .06). Aberrant expression for hMLH1
protein correlated well with stage (P  .0001), T status (P
 .008), and N status (P  .0001), whereas none of the
patients’ clinicopathologic parameters showed significant
correlation with aberrant expression of hMSH2 protein.
Figure 2. Kaplan-Meier survival curve with log-rank t
esophageal squamous cell carcinoma. Comparison
expression of hMLH1 and hMSH2 protein was shown
intervals for the hMLH1 and hMSH2 groups were 25.6
Figure 3. Representative results of promoter methyla
designated as U for the unmethylated product and M f
unmethylated hMLH1 were shown for the experimen
represents tumor sample. Tumor samples for patients 1
from patient 1, tumor sample from patient 2, and lymph
unmethylated gene control specimens were harvested from
1371.e4 The Journal of Thoracic and Cardiovascular Surgery ● NMedian survivals in months were as follows: 24  3.7 and
26 7.7 (standard error) for patients with unmethylated and
methylated hMLH1 genes (P .24); 29 1.7 and 15 6.3
for patients with normal and aberrant expression of hMLH1
protein (P  .18); and 29  5.0 and 23  6.7 for patients
with normal and aberrant expression of hMSH2 protein,
respectively (P  .40). No significant difference in survival
existed between patients with normal and aberrant expres-
sion of hMLH1 (P  .18) or hMSH2 protein (P  .40,
Figure 2).
Promoter Methylation of hMLH1 and its Association
With Clinicopathologic Parameters
A representative result is shown in Figure 3. All normal
mucosa control specimens showed only unmethylated
or 60 patients followed for 5 years after resection for
rvival between patients with normal and aberrant
and B, respectively. Ninety-five percent confidence
.4 and 19.2 to 38.8 months, respectively.
for hMHL1. Primer sets used for amplification were
ethylated genes. The data for lymphocytes containing
ontrol. N represents normal mucosa sample, and T
3 showed methylated hMLH1, whereas normal mucosa
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imens showed methylated hMLH1 (Table E2). In contrast to
the correlative analysis of protein expression, the methyl-
ation status of hMLH1 correlated well with stage (P .024)
and N status (P  .02) but not with T or M status (Table
E2).
Correlation of Promoter Methylation With Aberrant
Protein Expression of hMLH1
A concordance rate of 83.3% was observed between pro-
moter methylation and aberrant protein expression of
hMLH1 (P  .001, Table E3), indicating that promoter
methylation might play an important role in the inactivation
of protein expression for hMLH1.
Discussion
Impaired MMR DNA replication often leads to a mutant
phenotype of human cells6 and is believed to be involved in
carcinogenesis in some human cancers.9-14 Promoter meth-
ylation is an important mechanism that causes inactivation
of expression of DNA MMR genes, such as hMLH1, in
human cancers.10,12,13 Little is known about whether pro-
moter methylation of hMLH1 is associated with loss of
hMLH1 protein and whether aberrant expression of hMLH1
protein is involved in tumorigenesis of squamous cell car-
cinoma of the esophagus. Furthermore, there are no correl-
ative studies of aberrant expression of these MMR genes
and the prognosis of esophageal squamous cell cancer. To
address the above questions, we designed this study to
investigate promoter methylation of hMLH1 and expression
of hMLH1 and hMSH2 protein in squamous cell carcinoma
of the esophagus in relation to prognosis.
Aberrant expression of hMLH1 protein was observed in
a considerable number of our patients within the early and
late stages, suggesting that loss of hMLH1 protein is an
early event in tumorigenesis of esophageal squamous cell
cancer, and it persists as tumor progresses. Loss of hMSH2
protein was also observed in a considerable number of
patients, but it did not show significant correlation between
any of the patients’ clinicopathologic parameters. In con-
trast, aberrant expression of hMLH1 protein correlated well
with patients’ overall stage, T status, and N status. These
results suggest that expression of hMLH1 protein is a better
prognostic predictor than expression of hMSH2 protein.
Intriguingly, survival analysis did not show significant cor-
relation between patients with normal and aberrant expres-
sion of hMLH1 or hMSH2 protein. We speculated that
absence of correlation between survival and expression of
hMLH1 or hMSH2 protein might be attributed to the small
sample size studied.
A concordance of 83.3% observed between promoter
methylation of hMLH1 and its protein expression implies
that promoter methylation is an important mechanism that is
responsible for the inactivation of protein expression of
The Journal of Thoracic anhMLH1. Within the remaining 16.7% of discordance, 8
(13.3%) tumor samples presented with unmethylated pro-
moter of hMLH1 but aberrant expression of hMLH1 protein,
suggesting that there might be mechanisms other than pro-
moter methylation leading to inactivation of gene expres-
sion, such as loss of heterozygosity or splicing of mRNA
transcript, as reported previously.9,23 Our results support
previous results that suggest promoter methylation of the
hMLH1 as a major mechanism responsible for silencing of
its gene expression and an active player in carcinogenesis
for some human cancers.8-12 The majority of previous stud-
ies did not correlate results from molecular analyses with
patients’ clinicopathologic parameters or outcome, as we
did in the current study.
Promoter methylation with aberrant expression of hMLH1,
but not hMSH2, has been reported in gastrointestinal cancers,
including colorectal and gastric cancers.5,17There are limited
reports discussing the role of promoter methylation and altered
expression of hMLH1 or hMSH2 protein in esophageal cancer.
Evans and coworkers14 demonstrated loss of both hMLH1
and hMSH2 protein in 78% (21/27) of resected esophageal
adenocarcinomas, but they concluded that protein expres-
sion was not associated with tumor grade, pathologic stage,
or patient survival. Promoter methylation was not investi-
gated in their study. In comparison, we also demonstrated a
high frequency of aberrant protein expression of both
hMLH1 and hMSH2 and promoter methylation of hMLH1.
Unlike their results, a good correlation between aberrant
protein expression of hMLH1 and tumor stage and individ-
ual T and N status was observed in our study. In addition,
we showed a significant correlation between promoter
methylation of hMLH1 with patients’ stage and N status.
Differences in these 2 results might be attributed to different
types of cancers, different ethnic groups, and different sam-
ple sizes studied or to patient selection.
Results from studies related to methylation and protein
expression of the hMLH1 gene in squamous cell cancer of
the esophagus remain controversial. Nie and associates24
showed a frequency of hMLH1 methylation in 5 (20%) of
24 resected esophageal squamous cell carcinomas, but they
did not describe its protein expression. On the other hand,
Hayashi and colleagues25 reported a low frequency of 20%
for aberrant hMLH1 protein expression in 30 resected
esophageal squamous cell carcinoma samples. In that study
only 7 of the 30 resected tumor samples were analyzed for
methylation of the hMLH1 gene, and none of them was
methylated. In contrast, Kubo and coworkers26 reported a
high frequency (66.7%) of hMLH1 methylation and its
protein expression in 34 esophageal carcinomas associated
with other primary cancers but did not clarify their frequen-
cies in esophageal carcinoma alone. Discrepancies in these
results can be attributed to differences in patient selection,
different ethnic groups of patients, and possibly different
d Cardiovascular Surgery ● Volume 130, Number 5 1371.e5
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an association analysis for methylation and protein expres-
sion of the hMLH1 gene, nor did they show a good corre-
lation between gene methylation and protein expression
with patients’ clinicopathologic parameters, probably be-
cause of smaller sample sizes compared with that in our
series.
In conclusion, our results suggest that aberrant expres-
sion of hMLH1 and hMSH2 protein is frequently associated
with the presence of esophageal squamous cell carcinoma,
suggesting that loss of these 2 DNA MMR proteins is
involved in the tumorigenesis of this type of esophageal
cancer. Protein expression of hMLH1 is a better prognostic
predictor for resected squamous cell cancer of the esopha-
gus than protein expression of hMSH2. Promoter methyl-
ation is one of the mechanisms responsible for the inacti-
vation of hMLH1 protein expression and is a potential
molecular marker for squamous cell cancer of the esopha-
gus. Further studies with cell line or resected tissue samples
to elucidate other possible mechanisms of altered expres-
sion of the hMLH1 and hMSH2, including microsatellite
instability of the genes, loss of heterozygosity, and alter-
ations in mRNA transcription, might help us to understand
better the role of MMR system in the tumorigenesis of
squamous cell carcinoma of the esophagus.
We thank Dr Mark Ferguson at the University of Chicago for
his review of this manuscript.
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Discussion
Dr Stephen C. Yang (Baltimore, Md). Aberrant DNA methyl-
ation, as Dr Tzao has said, is the most common molecular lesion
of the cancer cell. The most studied change of DNA methylation
is the silencing of tumor suppressor genes, but now other cellular
mechanisms are being investigated, such as alterations in DNA
mismatch repair, as Dr Tzao and his colleagues have studied today.
From a translational standpoint, defective DNA mismatch repair
has important implications on the mechanisms of tumorigenesis
and the clinical behavior of tumors and can be used as a target for
anticancer agents, although tumor cells with defective mismatch
repair display reduce sensitivity to the cytotoxic effects of DNA
damaging agents, such as alkylating agents and cisplatin.
Over the past decade, there have been enormous efforts to
understand the molecular mechanisms of defective mismatch re-
pair in colon cancer, which have led to diagnostic tests to screen
these gene mutations and have aided the oncologist to apply
appropriate and specific regimens for tumor treatment. However,
similar data are lacking in the esophageal cancer model.
Dr Tzao, my first question addresses your unique results of the
high frequencies of hMLH1 and hMSH2 downregulation. Both are
very rarely simultaneously downregulated in cancer. Either a tu-
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Tzao et al General Thoracic Surgerymor mutates or epigenetically alters hMLH1 or hMSH2, but this is
one of the first reports I can find of both being downregulated with
such high frequencies of 72% and 65%, respectively. These fre-
quencies are difficult to explain from a tumor biology point of
view. In colorectal cancers, in which immunohistochemical anal-
ysis of these genes was first described by Lindor in 2002, he never
saw absences of both hMLH1 and hMSH2 together in more than
1100 cancers. The absence rates of immunohistochemical expres-
sion in most other cell types are less than 30%. Given your
unprecedented results, what are your thoughts on the proposed
mechanism of hMSH2 downregulation with hMLH1?
Dr Tzao. Thank you, Dr Yang, for the questions and important
comments. What you have referred to is probably that colorectal
cancer has a low incidence of hMLH1 expression. One of my
collaborators, Dr Yi-Ching Wang, published an article on lung
cancer lately in the Journal of Clinical Investigation, discussing
both hMLH1 and hMSH2. They found a significant frequency in
loss of expression of both of these 2 mismatch repair proteins. As
far as I know, there are no data presenting the status of protein
expression of these 2 proteins in parallel for squamous cell carci-
noma in the same report. Those were what we observed. At this
time, I have no good explanation as to the mechanism for loss of
both of these 2 proteins. One might speculate that discrepancies
could be attributed to differences in ethnic group, patient selection,
or a different type of cancer studied.
Dr Yang. In your article you provide an explanation of why
hMLH1 has reduced protein expression but provide no explanation
for hMSH2. Did you look at hMSH2 methylation? Is squamous
cell carcinoma unique in being deficient in DNA mismatch repair
activity?
Dr Tzao. I am sorry, can you rephrase that?
Dr Yang. Well, the first part of that question—you explained
why hMLH1 has reduced protein expression, but you did not do
that for hMSH2.
Dr Tzao. hMSH2 methylation has been previously studied in
other types of cancer, and it is rarely methylated, as reported by the
majority of those published works. That is one of the reasons that
we did not do the methylation assay for hMSH2. Another reason
for not performing this study actually is because our system was
not working out well at the time of this report, but we will keep
working on that to find out possible mechanisms that are respon-
sible for aberrant expression of hMSH2 protein.
Dr Yang. Finally, I have a clinical question. How many of the
patients in your cohort received adjuvant or neoadjuvant therapy?
If they did, how does this affect your survival curves?
Dr Tzao. We were expecting to see a separate curve for the
hMLH1 group, and actually, before 30 months, it appeared to
The Journal of Thoracic anseparate out, but after that, it seemed to converge together, making
the overall survival not significantly different. Our speculation to
this observation is probably because of the selection of our patients
because many of our patients were in the late stage, beyond stage
IIB, and were generally given postoperative adjuvant therapy but
did not improve in terms of survival. This might obscure a poten-
tial significant difference in survival. I believe that we need a
larger sample size, including a more even distribution in early and
late stages, to see whether there is a significant difference.
Dr Yang. Correct. That was one of the questions on that. On
the left-hand panel, there was a divergence in the first 15 months.
Dr Tzao. Yes, in the first 30 months of follow-up.
Dr Yang. Therefore you cannot explain that by stage or other
clinical factors, correct?
Dr Tzao. The explanation to your question, as I just mentioned,
is probably because of our selection of patients.
Dr Yang. Again, I want to thank the Association for the
privilege of discussing this article and congratulate you again on
your findings.
Dr Tzao. Thank you very much.
Dr King F. Kwong (Baltimore, Md). Dr Tzao, I congratulate
you and your colleagues on a fine foray into a very difficult area.
As you know, many genetic alterations and changes do not
always correlate in terms of expression, and being able to look at
the protein end of things really starts to get at the true mechanisms
of how these genetic changes work.
I have 2 very quick questions. First, as you know, the incidence
of adenocarcinoma is much more prevalent in our country, here as
well as in some western countries, which is very contradistinct
from in your country and in some of Asia. Have you looked at
some of these changes—protein expression—and these genetic
changes in adenocarcinoma? As you know, the difference between
adenocarcinoma and squamous cell carcinoma is perhaps very
different tumor biologies at play.
Dr Tzao. Thank you for the question.
In our country, it is interesting to tell you that we have more
than 80% of patients with squamous cell carcinoma. Very rarely do
we see esophageal adenocarcinoma. I have no explanation for why
there is a rarity of adenocarcinoma at this time. This is why we
focused on our patient population in which squamous cell carci-
noma predominates.
Dr Kwong. So you have not looked at this in adenocarcinoma?
Dr Tzao. No. There has been a study by Evans and associates,
and I think that is the only study on adenocarcinoma. In that study,
they do not look at the promoter methylation for hMLH1 but only
the protein expression in this type of esophageal cancer.Dr Kwong. Thank you.
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I 4 4/0 55.8 15.5 3/1 4/0 0/4 0/4 31.3 5.7
IIA 29* 32/3 63.5 9.7 26/3 27/2† 0/29 2/27 29.0 1.6
IIB 6 6/0 62.8 9.4 5/1 6/0 6/1 5/1 22.0 6.7
III 17* 17/0 66.8 10.2 17/2 15/2‡ 14/3 12/5 15.0 5.1
IV§ 4 4/0 53.5 9.1 4/1 4 0 3/1 2.0 1.5
TT/TH, Transthoracic/transhiatal; SE, standard error. *Surgical mortalities: there were 2 among patients with stage IIA disease and 1 among patients with
stage III disease, respectively. †These 2 patients were confirmed to have R1 resection postoperatively. ‡One patient was considered as having R2 resection
at the time of the operation, and the other was identified as having R1 resection postoperatively. §Two of them were staged as IVA because of a lower
thoracic lesion with celiac nodal metastasis, and the other 2 were staged as IVB on account of a midthoracic lesion with perigastric (n  1) and celiac
(n  1) nodal involvement, respectively.
TABLE E2. Comparison between promoter methylation, protein expression of hMLH1, and expression of hMSH2 protein and
clinicopathologic features for patients undergoing esophagectomy for squamous cell carcinoma of the esophagus
Characteristics
Methylation (hMLH1)* Protein (hMLH1)* Protein (hMSH2)†
Patients   (%)   (%)   (%)
Overall 60 23 37 (62) 17 43 (72) 21 39 (65)
Staging
III 39 19 20‡ 17 22§ 17 22
IIIIV 21 4 17 0 21 4 17
TNM
T12 20 11 9 11 9 8 12
T34 40 12 28 6 34 13 27
N0 35 17 18¶ 17 18# 13 22
N1 25 6 19 0 25 8 17
M0 56 22 34 17 39 20 36
M1 4 1 3 0 4 1 3
TNM: T, tumor invasion; N, regional lymph nodes; M, distant sites (metastases). *These groups represent patients with alteration in the hMLH1 gene/protein.
†These groups represent patients with hMSH2 protein. ‡P  .024 and §P  .0001, respectively, between stage III and IIIIV. P  .008 between stage
T1T2 and T3T4. ¶P  .02 and #P  .0001, respectively, between N0 and N1.





Aberrant 35 (58.3%)* 8 (13.3%)†
Normal 2 (3.3%)† 15 (25%)*
Concordant vs discordant Concordant: 50 (83.3%)* Discordant: 10 (16.7%)†
Data were presented as actual numbers and percentages of cases in a total of 60 patients. *Concordant: methylated/aberrant and unmethylated/normal.
†Discordant: unmethylated/aberrant and methylated/normal. P .001 for correlation between promoter methylation and protein expression of the hMLH1
gene.1371.e8 The Journal of Thoracic and Cardiovascular Surgery ● November 2005
